Back to Search

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment

  • Protocol Number: 201807178
  • Principal Investigator: Oh, Stephen
  • Cancer Types: Leukemia, Myeloma, and Hematologic

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions